Evidence map›Paper›PMID 40232151›Full record

ArticleCancer medicine2025

Bortezomib, Mitoxantrone Hydrochloride Liposome, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Multi-Center, Open-Label Phase I Trial.

Ya-Lan Zhou, Jin-Qiao Zhang, Wei Wang, Li Bao, Bai-Jun Fang, Da Gao, Li-Ping Su, Wen-Ming Chen, Guang-Zhong Yang

Registry-linked trialAbstract readClinical Trial, Phase IMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05052970 (A Phase Ⅰ Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Combination With Bortezomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05052970 phase1unknown statusnot on this map

A Phase Ⅰ Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Combination With Bortezomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

TypeinterventionalSponsorCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Ran2021 to 2024Enrolled60ConditionsRelapsed or Refractory Multiple MyelomaArmsMitoxantrone Hydrochloride Liposome injection, Bortezomib for Injection, Dexamethasone Acetate Tablets
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ya-Lan ZhouDepartment of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.ORCID https://orcid.org/0000-0002-7059-8277
Jin-Qiao ZhangDepartment of Hematology, The Third Hospital of Hebei Medical University, Hebei, China.
Wei WangDepartment of Hematology, The Second Affiliated Hospital of Harbin Medical University, Heilongjiang, China.
Li BaoDepartment of Hematology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China.ORCID https://orcid.org/0000-0002-6436-1492
Bai-Jun FangDepartment of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Henan, China.
Da GaoDepartment of Hematology, Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia, China.
Li-Ping SuDepartment of Hematology, Shanxi Provincial Cancer Hospital, Shanxi, China.
Wen-Ming ChenDepartment of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.ORCID https://orcid.org/0000-0001-6298-8489
Guang-Zhong YangDepartment of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.

Funding

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co. Ltd.National Natural Science Foundation of China 82100169
6 · The paper itself

Abstract

backgroundsMitoxantrone hydrochloride liposome (Lipo-MIT) has shown clinical benefits in various tumors. However, there is no prospective study evaluating its effectiveness and safety in relapsed/refractory multiple myeloma (RRMM). A phase I trial of bortezomib, Lipo-MIT, and dexamethasone (VMitD) with the primary endpoints being safety and efficacy was performed.

methodsTwenty subjects were enrolled this study, and the dose of Lipo-MIT was designed to be 12, 16, and 20 mg/m

resultsThe most common grade 3/4 non-hematologic adverse event was pneumonia (20%). The most frequently observed grade 3/4 hematologic toxicity included thrombocytopenia (70%), neutropenia (55%), lymphopenia (30%), and anemia (10%). Fifteen subjects received at least one efficacy evaluation, including 60% (9/15) with a very good partial response (VGPR) or better, resulting in an overall response rate (ORR) of 86.7% (13/15).

conclusionsThis is the first report about the novel triplet regimen VMitD, including Lipo-MIT for RRMM, which was well tolerated and demonstrated efficacy. Further studies are required to assess the outcomes more accurately and to evaluate its effectiveness in comparison to other salvage regimens containing proteasome inhibitors and anthracyclines.

trial registrationClinicalTrials.gov identifier: NCT05052970.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBortezomibDexamethasoneMitoxantroneMultiple MyelomaAdultAgedDrug Resistance, NeoplasmFemaleHumansLiposomesMaleMiddle AgedTreatment OutcomeBortezomibDexamethasoneLiposomesMitoxantroneefficacymitoxantrone hydrochloride liposomerelapsed/refractory multiple myelomasafety

Identifiers

PMID40232151
PMCPMC11998603

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.